HPV has been identified as a causal agent in oropharyngeal squamous cell carcinoma (OPSCC) with the incidence of HPV-related OPSCC increasing dramatically over the last several decades. As patients with HPV-positive OPSCC have a significantly better survival compared to patients with HPV-negative OPSCC, testing for HPV status is critical.
The RNAscope™ RNA In Situ Hybridization Platform, including chromogenic detection reagents and target-specific probes for both High Risk and Low Risk HPV types, provides clear and unequivocal assessment of HPV status in FFPE tissue. (Figure 1) In numerous peer-reviewed publications, the RNAscope HPV Detection Reagents have demonstrated significantly higher specificity and equivalent sensitivity in direct comparisons with p16 IHC for the presence of high-risk HPV in OPSCC.
The combination of high sensitivity and high specificity ensures ready identification of HPV-related tumors while reducing potential false positives that can result from the use of surrogate markers of HPV such as p16. Unlike p16 IHC, RNAscope allows the pathologist to interrogate any single HPV type or combination of HPV types.
>> Download the Application Note as a PDF
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
